Compare Crispr Therapeutics AG (CRSP) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while YieldMax Universe Fund of Option Income ETFs trades at $7.62 (market cap $364M). The key difference: Crispr Therapeutics AG is far larger — about 13.4× YieldMax Universe Fund of Option Income ETFs's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| CRSP | YMAX | |
|---|---|---|
Market Cap | $4.88B | $364M |
Volume | 2,861,747 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $74.92 | $12.98 |
52-Week Low | $44.34 | $7.27 |
Typical Hold Time | 77 Days | 56 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
YMAX trades at $7.61, up 1.06% with a bearish technical outlook. The ETF shows persistent NAV erosion despite weekly distributions, with the share price declining 22.7% year-to-date. Recent portfolio adjustments and a 40%+ annualized yield highlight structural concerns about distribution sustainability. Technical indicators show bearish moving averages and neutral oscillators with support at $7 and resistance at $8.
The outlook remains cautious due to ongoing principal erosion and high fees. While the high yield attracts income investors, the fund-of-funds structure adds layered costs. Analyst sentiment is neutral to bearish, with concerns about long-term viability outweighing short-term income benefits. Key risks include distribution policy sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
